Original Article
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
N Engl J Med 2013; 368:1800-1808May 9, 2013DOI: 10.1056/NEJMoa1205409
- Abstract
Background
Trials have shown a beneficial effect of n−3 polyunsaturated fatty acids in patients with a previous myocardial infarction or heart failure. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction.
Methods
In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 860 general practitioners in Italy. Eligible patients were men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction. Patients were randomly assigned to n−3 fatty acids (1 g daily) or placebo (olive oil). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 year, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes.
Results
Of the 12,513 patients enrolled, 6244 were randomly assigned to n−3 fatty acids and 6269 to placebo. With a median of 5 years of follow-up, the primary end point occurred in 1478 of 12,505 patients included in the analysis (11.8%), of whom 733 of 6239 (11.7%) had received n−3 fatty acids and 745 of 6266 (11.9%) had received placebo (adjusted hazard ratio with n−3 fatty acids, 0.97; 95% confidence interval, 0.88 to 1.08; P=0.58). The same null results were observed for all the secondary end points.
Conclusions
In a large general-practice cohort of patients with multiple cardiovascular risk factors, daily treatment with n−3 fatty acids did not reduce cardiovascular mortality and morbidity. (Funded by Società Prodotti Antibiotici and others; ClinicalTrials.gov number, NCT00317707.)
Media in This Article
Figure 1
Kaplan–Meier Curves for Death or First Hospitalization Due to Cardiovascular Cause.Figure 2
Effect of n−3 Polyunsaturated Fatty Acids on the Risk of Death or First Hospitalization Due to Cardiovascular Cause, According to Prespecified Subgroups.Article Activity
- Article
It has been suggested that the use of n−3 polyunsaturated fatty acids derived from fish may reduce the risk of cardiovascular disease by means of beneficial effects on arrhythmic, atherosclerotic, inflammatory, and thrombotic processes.1 A benefit of n−3 fatty acids in reducing cardiovascular mortality and morbidity has been documented in patients surviving a myocardial infarction2 and in patients with heart failure.3
The Risk and Prevention Study, conceived after completion of the Primary Prevention Project4 and a pilot study,5-7 was a double-blind, placebo-controlled trial assessing the efficacy of n−3 fatty acids in patients at high cardiovascular risk, as judged by a nationwide network of general practitioners in Italy. These studies reflect the view that general practice is the most representative setting for testing primary prevention strategies.
Methods
Study Design and Oversight
The background and design of the Risk and Prevention Study have been described in detail elsewhere.8 For this community-based trial, 860 general practitioners were selected because of their involvement in previous research projects4,9 or from general practitioner–investigator registries in local health units. The trial was designed by the steering committee (for a list of members, see the Supplementary Appendix, available with the full text of this article at NEJM.org) and approved by the ethics committees of the local health units. Standard operating procedures complied with the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonisation.10 An independent data and safety monitoring board oversaw the study and monitored patient safety, with a planned blind interim analysis when the investigators had reported half the expected number of end-point events.
The steering committee had the full and sole responsibility for planning and coordinating the study, analyzing and interpreting the data, and preparing the manuscript and submitting it for publication. Società Prodotti Antibiotici, Pfizer, and Sigma Tau funded the trial but had no role in the study design, planning, conduct, or analysis or in the interpretation or reporting of the results. All the authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of this report to the trial protocol, which is available at NEJM.org.
Study Participants
Eligible patients were men and women who met at least one of the following criteria: multiple cardiovascular risk factors, clinical evidence of atherosclerotic vascular disease, or any other condition putting the patient at high cardiovascular risk in the opinion of the patient's general practitioner. The criterion of multiple cardiovascular risk factors was defined as at least four of the following (or, for patients with diabetes, at least one of the following): an age of 65 years or older, male sex, hypertension (clinical history of hypertension or use of antihypertensive treatment), hypercholesterolemia (clinical history of hypercholesterolemia or use of lipid-lowering treatment), status as a current smoker, obesity (a body-mass index [the weight in kilograms divided by the square of the height in meters] of 30 or more), or a family history of premature cardiovascular disease (defined as cardiovascular disease at <55 years of age in the patient's father or a brother or at <65 years of age in the patient's mother or a sister). Clinical evidence of atherosclerotic vascular disease was defined as angina pectoris, peripheral artery disease, a history of ischemic stroke or transient ischemic attack, or previous treatment with an arterial revascularization procedure.
Exclusion criteria were previous myocardial infarction, hypersensitivity to n−3 fatty acids, pregnancy, clinical conditions with poor short-term prognosis, and conditions that would affect the ability to provide informed consent or comply with the protocol. All patients coming to the attention of one of the participating general practitioners and meeting the criteria for inclusion in the study were consecutively enrolled over a period of time that was prespecified by each general practitioner. All patients provided written informed consent before enrollment.
Study Procedures
Study patients were randomly assigned to receive one capsule daily containing 1 g of n−3 fatty acids (polyunsaturated fatty acid ethyl esters with eicosapentaenoic acid and docosahexaenoic acid content not <85%, in a ratio that could range from 0.9:1 to 1.5:1) or placebo (olive oil). Treatment was centrally assigned by means of telephone on the basis of a concealed, computer-generated randomization list, stratified according to general practitioner. Patients, general practitioners, coordination and statistical staff, and outcome assessors were unaware of the study assignments until the final analyses were completed.
At baseline and at the scheduled yearly follow-up visits, the patient's general practitioner collected prespecified study information, including anthropometric measures, blood pressure, heart rate, lifestyle habits, current clinical conditions, any new diagnosis of cardiovascular disease, essential laboratory tests, current medical therapies, treatment compliance (according to patient self-report), and clinical outcomes. During these visits, the general practitioner also evaluated the patient for the presence and treatment of cardiovascular risk factors and considered, in light of current guidelines, how to reduce the patient's overall cardiovascular risk. Patients whose treatment was stopped for any reason were followed until the end of the study.
End Points
At the beginning of the trial, the primary efficacy end point was defined as the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke.8 However, after a blinded assessment at 1 year showed an event rate that was lower than expected, the primary efficacy end point was revised as the composite of time to death from cardiovascular causes or hospital admission for cardiovascular causes.
Secondary efficacy measures included the composite of time to death, nonfatal myocardial infarction, or nonfatal stroke (the original primary end point); the composite of time to death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke; death from coronary heart disease; and sudden death from cardiac causes (see the Supplementary Appendix for definitions). Fatal and nonfatal coronary events and major ventricular arrhythmic events were included in preplanned exploratory analyses. All events included in the primary efficacy end point were documented with the use of a narrative summary and supporting documentation and were adjudicated on the basis of prespecified criteria by an ad hoc committee consisting of a cardiologist, an internist, and a neurologist who were unaware of the study assignments. All serious adverse events, including those that were not necessarily related to the study drugs, were reported.
Statistical Analysis
The primary efficacy end point was initially defined as the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke; the event rate was expected to be 2% per year. However, on blinded assessment at 1 year, the event rate was lower than expected, at 1.4% per year.8 Therefore, the primary end point was redefined as the time to death from cardiovascular causes or first hospital admission for cardiovascular causes. For this revised primary end point, we assumed an event rate in the placebo group of 15% at 5 years and a relative risk reduction of 15%, with a withdrawal rate of 10%. We adopted an event-driven design; to achieve a power of 90% at an alpha level of 0.05, a total of 1383 events were necessary to close the trial, which required an enrollment of approximately 11,200 patients. However, we decided that randomization could continue until all the participating general practitioners had had the opportunity to recruit patients.
Baseline characteristics of the patients who underwent randomization were compared by means of the chi-square test for categorical variables and the t-test or nonparametric test for continuous variables. Changes from baseline to 5 years in systolic and diastolic blood pressure; heart rate; total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol levels; triglyceride levels; and blood glucose and glycated hemoglobin levels were assessed by means of analysis of variance, with adjustment for baseline values, and were reported as least-square means (±SE).
Analyses were performed in the intention-to-treat population, except for a prespecified per-protocol analysis of the primary end point in patients with no major protocol violations who did not permanently stop treatment. Treatment effect on the study end points was analyzed by fitting Cox proportional-hazards models. Unadjusted hazard ratios and 95% confidence intervals were calculated for analyses of the primary and secondary end points and for the prespecified subgroup analyses. For the primary end point, results are also reported as hazard ratios adjusted for baseline variables that were unbalanced (P<0.05) between the study groups. The assumption of proportional hazards for the randomly assigned treatments was assessed by estimating the log(−log[survival distribution]) plotted against the log(failure time) and by the time-dependent covariate test. Kaplan–Meier estimates of survival curves were based on the results of the log-rank test.
The effect of the study treatment on the primary end point was assessed in subgroups defined by risk level or coexisting condition, age (<65 years vs. ≥65 years), sex, and inclusion criteria. We performed Cox analyses of the primary outcome in subgroups by fitting a Cox model with one term representing the study group, one representing the covariate of interest, and an interaction term to test for heterogeneity of the effect of n−3 fatty acids. All reported P values are two-sided. All analyses were performed with the use of SAS software, version 9.2 (SAS Institute).
Results
Trial Participants
Between February 2004 and March 2007, a total of 12,513 patients were enrolled in the trial, of whom 6244 were randomly assigned to n−3 fatty acids and 6269 to placebo. A total of 12,505 patients were included in the intention-to-treat analyses, of whom 6239 received n−3 fatty acids and 6266 received placebo (see Fig. S1 in the Supplementary Appendix for the flow diagram).
Baseline characteristics are reported in Table 1Table 1
Baseline Characteristics of the Intention-to-Treat Population, According to Study Group., and in Table S1 in the Supplementary Appendix. The mean age was 64.0 years, and 61.5% of the patients were men. The most common inclusion criterion was diabetes mellitus plus one or more cardiovascular risk factors, present in 5986 patients (47.9%); 3691 patients (29.5%) had a history of atherosclerotic disease, 2602 (20.8%) had at least four cardiovascular risk factors excluding diabetes, and 226 (1.8%) had an increased cardiovascular risk according to the judgment of the general practitioner.Cardiovascular Risk Factors and Medications
By the end of the trial, the overall cardiovascular-risk profile had improved in both groups (Table S2 in the Supplementary Appendix). The plasma triglyceride level fell significantly more in patients given n−3 fatty acids than in those who received placebo (−28.2±1.3 mg per deciliter vs. −20.1±1.3 mg per deciliter, P<0.001). There was a slight increase in the HDL level in patients who received n−3 fatty acids. There were no significant differences in blood pressure, heart rate, total and LDL cholesterol levels, or blood glucose or glycated hemoglobin levels between the two groups. Prescriptions of recommended cardiovascular drugs increased during follow-up to a similar degree in the two study groups (Table S3 in the Supplementary Appendix).
Efficacy End Points
The follow-up period ended on October 31, 2011, after a median duration of 5.0 years (interquartile range, 4.0 to 5.5). The primary end point occurred in 1478 patients (11.8%), including 733 of 6239 who received n−3 fatty acids (11.7%) and 745 of 6266 who received placebo (11.9%). The incidence of the primary end point was not significantly reduced by n−3 fatty acids (adjusted hazard ratio, 0.97; 95% confidence interval [CI], 0.88 to 1.08; P=0.58) (Table 2Table 2
Primary and Secondary Outcomes. and Figure 1Figure 1Kaplan–Meier Curves for Death or First Hospitalization Due to Cardiovascular Cause.).By the end of the study, 1115 patients who received n−3 fatty acids (17.9%) had stopped treatment, as had 1218 of those who received placebo (19.4%) (Table 3Table 3
Permanent Discontinuation of Study Treatment and Reasons for Discontinuation.). In the per-protocol analysis, which included the remaining 10,172 patients, there were 527 primary end-point events among patients who received n−3 fatty acids (10.3% of patients) and 510 among those who received placebo (10.1%) (hazard ratio, 1.01; 95% CI, 0.89 to 1.14; P=0.89).The rates of secondary end points were also similar in the two study groups (Table 2). Death from cardiovascular causes occurred in 142 patients who received n−3 fatty acids (2.3%), as compared with 137 patients who received placebo (2.2%; hazard ratio, 1.03; 95% CI, 0.82 to 1.30; P=0.80). Sudden death from cardiac causes occurred in 49 patients who received n−3 fatty acids (0.8%) and in 40 who received placebo (0.6%; hazard ratio, 1.22; 95% CI, 0.80 to 1.85; P=0.36). There was no significant difference between the two groups in the proportion of patients who died from any of the other identified causes (Table S4 in the Supplementary Appendix). There was no significant difference in the number of hospital admissions for cardiovascular causes (620 in the group of patients who received n−3 fatty acids [9.9%] and 630 in the placebo group [10.1%]; hazard ratio, 0.98; 95% CI, 0.87 to 1.09; P=0.68), but there were significantly fewer admissions for heart failure among patients who received n−3 fatty acids than among those who received placebo (96 patients [1.5%] vs. 142 patients [2.3%], P=0.002) (Table S5 in the Supplementary Appendix).
In the prespecified subgroup analyses, there was a significant interaction between the efficacy of n−3 fatty acids and sex (P=0.04 for interaction). The event rate for the primary end point was lower among women than among men, with a significantly lower rate of events among those who received n−3 fatty acids than among those who received placebo (hazard ratio, 0.82; 95% CI, 0.67 to 0.99; P=0.04) (Figure 2Figure 2
Effect of n−3 Polyunsaturated Fatty Acids on the Risk of Death or First Hospitalization Due to Cardiovascular Cause, According to Prespecified Subgroups.).A post hoc analysis of the efficacy of n−3 fatty acids in relation to baseline fish consumption (Table S6 in the Supplementary Appendix) showed no significant heterogeneity (P=0.46 for interaction). Post hoc subgroup analyses of the interaction of treatment with n−3 fatty acids in relation to aspirin use and statin use at baseline showed no evidence of interaction with these drugs (P=0.34 and P=0.28 for interaction, respectively).
Adverse Events
Gastrointestinal side effects (abdominal pain, nausea, diarrhea, and other symptoms) were the most frequently reported adverse drug reactions, but the incidence did not differ significantly between the two groups (Table 3). The investigators attributed two cases of severe epistaxis, both in patients who were also receiving anticoagulant or antiplatelet therapy, to the experimental treatment. Among the serious adverse events, there were 490 diagnoses of cancer among patients who received n−3 fatty acids (7.9% of patients) and 453 among those who received placebo (7.2%, P=0.19); bleeding occurred in 16 patients who received n−3 fatty acids (0.3%) and in 12 who received placebo (0.2%, P=0.44).
Discussion
The Risk and Prevention Study tested the hypothesis that n−3 fatty acids, which have been shown to be beneficial in patients who have had a myocardial infarction (in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico [GISSI]–Prevenzione study2) or heart failure (in the GISSI Heart Failure [GISSI-HF] study3), would be effective in reducing cardiovascular risk among patients who were treated according to the standard of care and who had multiple cardiovascular risk factors or atherosclerotic disease but no previous myocardial infarction. Our findings provide no evidence of the usefulness of n−3 fatty acids for preventing cardiovascular death or disease in this population.
The consistently null effect across the various end points and subgroups does not suggest alternative interpretations, but a few epidemiologic observations are useful. The overall frequency of hard end points (particularly the rates of sudden death from cardiac causes and death from coronary causes), on which n−3 fatty acids showed a clear benefit in the GISSI–Prevenzione study,2 was substantially lower than expected,8 possibly reflecting a country-specific low cardiovascular-risk profile (particularly with regard to dietary habits) and the rather intensive exposure of our study population to preventive treatments with further improvement during the 5-year follow-up period. Death from cardiovascular causes at 5 years made up only 18.7% of the primary composite end point. In addition, hospital admissions for cardiovascular causes were concentrated among patients 65 years of age or older and were rarely predictive of death: only 7.7% of patients admitted to the hospital for a cardiovascular cause died from cardiovascular causes during the trial.
The only two significant results (a reduction in hospital admissions for heart failure with n−3 fatty acids and their preventive effect in women) must be considered conservatively. Both may be due to chance, although they are consistent with two findings from other studies: the beneficial effect of n−3 fatty acids in patients with heart failure in the GISSI-HF study3 and the decrease in nonfatal coronary events in patients with hypercholesterolemia, the majority of whom were women, in the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).11 Our results are more consistent with the null findings of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, which tested supplementation with n−3 fatty acids in patients with dysglycemia.12
Although the reasons for the discrepancy between the null results of our study and the results of the GISSI–Prevenzione and GISSI-HF trials2,3 remains to be determined, a possible explanation can be hypothesized. The beneficial effect of n−3 fatty acids in those two trials was due to a reduction in sudden deaths from cardiac causes. It is conceivable that the effects of n−3 fatty acids become manifest primarily in patients who are particularly prone to ventricular arrhythmic events (e.g., those with a myocardial scar or left ventricular dysfunction). Our trial had extremely limited power to detect a reduction in sudden deaths from cardiac causes or arrhythmic events. The safety profile of n−3 fatty acids in this population of older persons who are already receiving many treatments for chronic disease could be of interest for their use in patient populations that are more prone to fatal and nonfatal arrhythmic events.2,3,13
In summary, we conducted a randomized trial of n−3 fatty acids in a large population of patients with multiple cardiovascular risk factors but no history of myocardial infarction. The trial incorporated systematic efforts to optimize medical therapies and control cardiovascular risk factors. On the basis of the results, we conclude that there was no significant benefit of n−3 fatty acids in reducing the risk of death from cardiovascular causes or hospital admission for cardiovascular causes.
Supported by Società Prodotti Antibiotici, Pfizer, and Sigma-Tau.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
The members of the writing group, who are listed in the Appendix, assume responsibility for the content and integrity of this article.
This article was updated on May 9, 2013, at NEJM.org.
We thank the women and men who agreed to participate in the study; F. Clerici, B. Ferri, A. Flamminio, A. Palumbo, C. Pera, A. Polidoro, and G. Sgaroni for help in the conduct of the study; and J.D. Baggott for editing an earlier draft of the manuscript.
Source Information
Address reprint requests to the Risk and Prevention Study Office, IRCCS–Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy, or to rep@marionegri.it.
The investigators of the Risk and Prevention Study Collaborative Group are listed in the Supplementary Appendix, available at NEJM.org.
Appendix
The members of the writing group are as follows: Maria Carla Roncaglioni, M.Sc., Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)–Istituto di Ricerche Farmacologiche Mario Negri, Milan; Massimo Tombesi, M.D., Centro Studi e Ricerche in Medicina Generale, Monza; Fausto Avanzini, M.D., IRCCS–Istituto di Ricerche Farmacologiche Mario Negri, Milan; Simona Barlera, M.Sc., IRCCS–Istituto di Ricerche Farmacologiche Mario Negri, Milan; Vittorio Caimi, M.D., Centro Studi e Ricerche in Medicina Generale, Monza; Paolo Longoni, M.D., Centro Studi e Ricerche in Medicina Generale, Monza; Irene Marzona, M.Sc., IRCCS–Istituto di Ricerche Farmacologiche Mario Negri, Milan; Valentina Milani, M.Sc., IRCCS–Istituto di Ricerche Farmacologiche Mario Negri, Milan; Maria Giuseppina Silletta, M.Sc., Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti; Gianni Tognoni, M.D., Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti; and Roberto Marchioli, M.D., Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti — all in Italy.
- References
References
1
De Caterina R
Full Text | Web of Science | Medline2
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardicoDietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-455[Erratum, Lancet 2001;357:642, 2007;369:106.]
CrossRef | Web of Science | Medline3
GISSI-HF Investigators
CrossRef | Web of Science | Medline4
Collaborative Group of the Primary Prevention Project
CrossRef | Web of Science | Medline5
Roncaglioni MC Avanzini F Roccatagliata D
CrossRef | Web of Science | Medline6
Roccatagliata D Avanzini F Monesi L
CrossRef | Medline7
Monesi L Avanzini F Barlera S
CrossRef | Web of Science | Medline8
Rischio and Prevenzione Investigators
CrossRef | Web of Science | Medline9
Avanzini F Alli C Bettelli G
CrossRef | Web of Science | Medline10
International Conference on Harmonisation home page (http://www.ich.org).
11
Yokoyama M Origasa H Matsuzaki M
CrossRef | Web of Science | Medline12
The ORIGIN Trial Investigators
Free Full Text | Web of Science | Medline13
Marchioli R Barzi F Bomba E
CrossRef | Web of Science | Medline
- Citing Articles (95)
Citing Articles
1
Mason W.Freeman, Geoffrey A.Walford. Lipoprotein Metabolism and the Treatment of Lipid Disorders. 2016:, 715-736.e7.
CrossRef2
Michel P.Hermans, EvaristeBouenizabila, Daniel K.Amoussou-guenou, Sylvie A.Ahn, Michel F.Rousseau. (2015) Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. Cardiovascular Diabetology 14
CrossRef3
PriyaKohli. (2015) Primary and Secondary Prevention of Ischemic Heart Disease in Women. Current Atherosclerosis Reports 17
CrossRef4
RichardKones, UmmeRumana. (2015) Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. Drugs 75, 1201-1228
CrossRef5
Kenneth M.Borow, John R.Nelson, Richard PrestonMason. (2015) Biologic Plausibility, Cellular Effects, and Molecular Mechanisms of Eicosapentaenoic Acid (EPA) in Atherosclerosis. Atherosclerosis
CrossRef6
Ángel A.García, ÓscarMúñoz, Daniel G.Fernández, Angélica M.Higuera, Álvaro J.Ruiz, Pablo A.Montoya, Juan M.Toro, Juan M.Arteaga, Alonso M.Villamizar, GregorioSánchez, YadiraVillalba. (2015) Alternativas terapéuticas al manejo farmacológico con estatinas en adultos con dislipidemia. Revisión sistemática de la literatura y recomendaciones generales. Revista Colombiana de Cardiología
CrossRef7
Matthew K.Ito. (2015) Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis
CrossRef8
AmirHassan, NadeemTajuddin, AliShaikh. (2015) Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl. Cardiology and Therapy 4, 83-93
CrossRef9
Rae-Ellen W.Kavey. (2015) Combined Dyslipidemia in Childhood. Journal of Clinical Lipidology
CrossRef10
AmedeoLonardo, StefanoBallestri, GiovanniTargher, PaolaLoria. (2015) Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 9, 629-650
CrossRef11
Eliot A.Brinton. (2015) Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. Cardiology Clinics 33, 309-323
CrossRef12
Markus J.Takkunen, Ursula S.Schwab, Vanessa D. F.de Mello, Johan G.Eriksson, JaanaLindström, JaakkoTuomilehto, Matti I. J.Uusitupa. (2015) Longitudinal associations of serum fatty acid composition with type 2 diabetes risk and markers of insulin secretion and sensitivity in the Finnish Diabetes Prevention Study. European Journal of Nutrition
CrossRef13
GiuseppeDerosa, PamelaMaffioli. (2015) Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. Expert Review of Endocrinology & Metabolism 10, 297-304
CrossRef14
Peter AlterProf, TobiasGlück, Jens H.Figiel, A. RembertKoczulla, Claus F.Vogelmeier, HeinzRupp. (2015) From heart failure to highly unsaturated fatty acid deficiency and vice versa – bidirectional heart and liver interactions. Canadian Journal of Cardiology
CrossRef15
Jacquelyn H.Flaskerud. (2015) Mood and Food. Issues in Mental Health Nursing 36, 307-310
CrossRef16
PasqualeLosurdo, AndreaGrillo, EmilianoPanizon, MichelaZanetti, MorenoBardelli, GianniBiolo, BrunoFabris, RenzoCarretta. (2015) Baroreflex sensitivity and central hemodynamics after omega-3 polyunsaturated fatty acids supplementation in an animal model of menopause. Vascular Pharmacology
CrossRef17
Aruna D.Pradhan, JoAnn E.Manson. (2015) Update on the Vitamin D and OmegA-3 trial (VITAL). The Journal of Steroid Biochemistry and Molecular Biology
CrossRef18
PaulNestel, PeterClifton, DavidColquhoun, MannyNoakes, Trevor A.Mori, DavidSullivan, BethThomas. (2015) Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease. Heart, Lung and Circulation
CrossRef19
AkiraSekikawa, Margaret F.Doyle, Lewis H.Kuller. (2015) Recent findings of long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFAs) on atherosclerosis and coronary heart disease (CHD) contrasting studies in Western countries to Japan. Trends in Cardiovascular Medicine
CrossRef20
Alberta N. A.Aryee, Joyce IreneBoye. Role and Importance of Health Claims in the Nutraceutical and Functional Food Markets. 2015:, 347-374.
CrossRef21
Alberta N. A.Aryee, Joyce IreneBoye. Current and Emerging Trends in the Formulation and Manufacture of Nutraceuticals and Functional Food Products. 2015:, 1-63.
CrossRef22
JulianHalcox, AnoopMisra. (2015) Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?. Metabolic Syndrome and Related Disorders 13, 1-21
CrossRef23
SrinivasanDasarathy, JaividhyaDasarathy, AmerKhiyami, LisaYerian, CarolHawkins, RuthSargent, Arthur J.McCullough. (2015) Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology 49, 137-144
CrossRef24
Laurade Keizer, Clara K.Chow. Diet Modification After Acute Coronary Events. 2015:, 323-334.
CrossRef25
Clemensvon Schacky. (2015) Omega-3 fatty Acids in cardiovascular disease – An uphill battle. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 92, 41-47
CrossRef26
V.Pallarés-Carratalá, V.Pascual-Fuster, D.Godoy-Rocatí. (2015) Dislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias. SEMERGEN - Medicina de Familia
CrossRef27
AmrRaghban, JenniferKirsop, W. H. WilsonTang. (2015) Prevention of Heart Failure in Patients with Chronic Kidney Disease. Current Cardiovascular Risk Reports 9
CrossRef28
F. D.Provenza, P.Gregorini, P. C. F.Carvalho. (2015) Synthesis: foraging decisions link plants, herbivores and human beings. Animal Production Science 55, 411
CrossRef29
C. M.DeGiorgio, P. R.Miller, R.Harper, J.Gornbein, L.Schrader, J.Soss, S.Meymandi. (2015) Fish oil (n-3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study. Journal of Neurology, Neurosurgery & Psychiatry 86, 65-70
CrossRef30
Emily V.Nosova, Michael S.Conte, S. MarleneGrenon. (2015) Advancing beyond the “heart-healthy diet” for peripheral arterial disease. Journal of Vascular Surgery 61, 265-274
CrossRef31
AkiraSekikawa, YoshihiroMiyamoto, KatsuyukiMiura, KunihiroNishimura, Bradley JWillcox, Kamal HMasaki, BeatrizRodriguez, Russell PTracy, TomonoriOkamura, Lewis HKuller. (2015) Continuous decline in mortality from coronary heart disease in Japan despite a continuous and marked rise in total cholesterol: Japanese experience after the Seven Countries Study. International Journal of Epidemiology, dyv143
CrossRef32
G.Assmann, P.Buono, A.Daniele, E.Della Valle, E.Farinaro, G.Ferns, V.Krogh, D.Kromhout, L.Masana, J.Merino, G.Misciagna, S.Panico, G.Riccardi, A.A.Rivellese, F.Rozza, F.Salvatore, V.Salvatore, S.Stranges, M.Trevisan, B.Trimarco, C.Vetrani. (2014) Functional foods and cardiometabolic diseases. Nutrition, Metabolism and Cardiovascular Diseases 24, 1272-1300
CrossRef33
NobuakiTanaka, TatsuroIshida, ManabuNagao, TakeshigeMori, TomokoMonguchi, MakiSasaki, KentaMori, KensukeKondo, HidetoNakajima, TomoyukiHonjo, YasuhiroIrino, RyujiToh, MasakazuShinohara, Ken-ichiHirata. (2014) Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis 237, 577-583
CrossRef34
AmitaSingh, MichaelDavidson. (2014) Combination Therapy with Statins. Endocrinology and Metabolism Clinics of North America 43, 993-1006
CrossRef35
HuanhuZhu, MinHan. (2014) Exploring Developmental and Physiological Functions of Fatty Acid and Lipid Variants Through Worm and Fly Genetics. Annual Review of Genetics 48, 119-148
CrossRef36
S.S.L.Leung Yinko, G.Thanassoulis, K.D.Stark, M.Avgil Tsadok, J.C.Engert, L.Pilote. (2014) Omega-3 fatty acids and the genetic risk of early onset acute coronary syndrome. Nutrition, Metabolism and Cardiovascular Diseases 24, 1234-1239
CrossRef37
IchiroTatsuno. (2014) Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia. Expert Review of Cardiovascular Therapy 12, 1261-1268
CrossRef38
Owais A.Khawaja, John M.Gaziano, LucDjoussé. (2014) N-3 Fatty Acids for Prevention of Cardiovascular Disease. Current Atherosclerosis Reports 16
CrossRef39
ThomasS. Metkus, Todd T.Brown, WendyS. Post. (2014) Cardiovascular Disease Associated with the Human Immunodeficiency Virus: An Update. Current Treatment Options in Cardiovascular Medicine 16
CrossRef40
Howard S.Weintraub. (2014) Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia. Postgraduate Medicine 126, 7-18
CrossRef41
Nisar A.Shaikh, JasonYantha, SabahShaikh, WilliamRowe, MaggieLaidlaw, CarlaCockerline, AbbasAli, BruceHolub, GeorgeJackowski. (2014) Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN® REVEAL Trial. Molecular and Cellular Biochemistry 396, 9-22
CrossRef42
TrygveHausken, Janneche UtneSkaare, AnuschkaPolder, MargarethaHaugen, Helle M.Meltzer, Anne-KatrineLundebye, KåreJulshamn, OttarNygård, Rolf K.Berge, JonSkorve. (2014) High Consumption of Farmed Salmon Does Not Disrupt the Steady State of Persistent Organic Pollutants (POP) in Human Plasma and Adipose Tissue. Journal of Toxicology and Environmental Health, Part A 77, 1229-1250
CrossRef43
Philip C.Calder. (2014) Very long chain omega-3 (n-3) fatty acids and human health. European Journal of Lipid Science and Technology 116:10.1002/ejlt.v116.10, 1280-1300
CrossRef44
Michael J.James, Thomas R.Sullivan, Robert G.Metcalf, Leslie G.Cleland. (2014) Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients. British Journal of Nutrition 112, 812-820
CrossRef45
J.Assies, R. J. T.Mocking, A.Lok, H. G.Ruhé, F.Pouwer, A. H.Schene. (2014) Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatrica Scandinavica 130:10.1111/acps.2014.130.issue-3, 163-180
CrossRef46
James K.Cooper. (2014) Nutrition and the brain: what advice should we give?. Neurobiology of Aging 35, S79-S83
CrossRef47
Samuel S.Gidding, CarolProspero, JobayerHossain, FrancesZappalla, Prabhakaran (Babu)Balagopal, BonitaFalkner, PeterKwiterovich. (2014) A Double-Blind Randomized Trial of Fish Oil to Lower Triglycerides and Improve Cardiometabolic Risk in Adolescents. The Journal of Pediatrics 165, 497-503.e2
CrossRef48
Christopher J.Shanahan, Robertde Lorimier. (2014) From Science to Finance—A Tool for Deriving Economic Implications from the Results of Dietary Supplement Clinical Studies. Journal of Dietary Supplements, 140828073351002
CrossRef49
Paul MRidker. (2014) LDL cholesterol: controversies and future therapeutic directions. The Lancet 384, 607-617
CrossRef50
Mariana VerdelhoMachado, HelenaCortez-Pinto. (2014) Management of fatty liver disease with the metabolic syndrome. Expert Review of Gastroenterology & Hepatology 8, 487-500
CrossRef51
Peter L.McLennan. (2014) Cardiac physiology and clinical efficacy of dietary fish oil clarified through cellular mechanisms of omega-3 polyunsaturated fatty acids. European Journal of Applied Physiology 114, 1333-1356
CrossRef52
KeikoKondo, KatsutaroMorino, YoshihikoNishio, MotoyukiKondo, KeikoNakao, FumiyukiNakagawa, AtsushiIshikado, OsamuSekine, TakeshiYoshizaki, AtsunoriKashiwagi, SatoshiUgi, HiroshiMaegawa. (2014) A fish-based diet intervention improves endothelial function in postmenopausal women with type 2 diabetes mellitus: A randomized crossover trial. Metabolism 63, 930-940
CrossRef53
Dick C.Chan, P. Hugh R.Barrett, Gerald F.Watts. (2014) The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Practice & Research Clinical Endocrinology & Metabolism 28, 369-385
CrossRef54
GeorgeMichas, RenataMicha, AntonisZampelas. (2014) Dietary fats and cardiovascular disease: Putting together the pieces of a complicated puzzle. Atherosclerosis 234, 320-328
CrossRef55
L. G.Hemkens, H. C.Bucher. (2014) HIV infection and cardiovascular disease. European Heart Journal 35, 1373-1381
CrossRef56
SoressaKitessa, MahindaAbeywardena, ChakraWijesundera, PeterNichols. (2014) DHA-Containing Oilseed: A Timely Solution for the Sustainability Issues Surrounding Fish Oil Sources of the Health-Benefitting Long-Chain Omega-3 Oils. Nutrients 6, 2035-2058
CrossRef57
J. E.Kaikkonen, P.Kresanov, M.Ahotupa, A.Jula, V.Mikkilä, J. S. A.Viikari, M.Kähönen, T.Lehtimäki, O. T.Raitakari. (2014) High serum n6 fatty acid proportion is associated with lowered LDL oxidation and inflammation: The Cardiovascular Risk in Young Finns Study. Free Radical Research 48, 420-426
CrossRef58
(2014) Chapter 4. Lifestyle modifications. Hypertension Research 37, 286-290
CrossRef59
TengfeiZheng, JingZhao, YushuWang, WennanLiu, ZhihaoWang, YuanyuanShang, WeiZhang, YunZhang, MingZhong. (2014) The limited effect of omega-3 polyunsaturated fatty acids on cardiovascular risk in patients with impaired glucose metabolism: A meta-analysis. Clinical Biochemistry 47, 369-377
CrossRef60
J. H. Y.Wu, D.Mozaffarian. (2014) -3 Fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle. Heart 100, 530-533
CrossRef61
Mark F.McCarty, James J.DiNicolantonio, Carl J.Lavie, James H.O’Keefe. (2014) Omega-3 and Prostate Cancer: Examining the Pertinent Evidence. Mayo Clinic Proceedings 89, 444-450
CrossRef62
Jean-MarieBourre. (2014) À propos de l’effet additionnel des oméga 3 chez des patients cardiaques multimédiqués. Pratiques en nutrition 10, 40-43
CrossRef63
JingPang, Dick CChan, Gerald FWatts. (2014) Critical review of non-statin treatments for dyslipoproteinemia. Expert Review of Cardiovascular Therapy 12, 359-371
CrossRef64
HuirongJing, JihongYao, XingmingLiu, HuiFan, FengZhang, ZhenluLi, XiaofengTian, YunZhou. (2014) Fish-oil emulsion (omega-3 polyunsaturated fatty acids) attenuates acute lung injury induced by intestinal ischemia–reperfusion through Adenosine 5′-monophosphate-activated protein kinase–sirtuin1 pathway. Journal of Surgical Research 187, 252-261
CrossRef65
Philip C.Calder, Richard J.Deckelbaum. (2014) Dietary fatty acids in health and disease. Current Opinion in Clinical Nutrition and Metabolic Care 17, 111-115
CrossRef66
YvesBoirie, BéatriceMorio, ElodieCaumon, Noël J.Cano. (2014) Nutrition and protein energy homeostasis in elderly. Mechanisms of Ageing and Development 136-137, 76-84
CrossRef67
FranciscoMarín, ÓscarDíaz-Castro, Juan MiguelRuiz-Nodar, Bernardo Garcíade la Villa, AlessandroSionis, JavierLópez, AntonioFernández-Ortiz, ManuelMartínez-Sellés. (2014) Actualización en cardiopatía isquémica y cuidados críticos cardiológicos. Revista Española de Cardiología 67, 120-126
CrossRef68
Clemensvon Schacky. (2014) Omega-3 Index and Cardiovascular Health. Nutrients 6, 799-814
CrossRef69
FranciscoMarín, ÓscarDíaz-Castro, Juan MiguelRuiz-Nodar, Bernardo Garcíade la Villa, AlessandroSionis, JavierLópez, AntonioFernández-Ortiz, ManuelMartínez-Sellés. (2014) Update on Ischemic Heart Disease and Critical Care Cardiology. Revista Española de Cardiología (English Edition) 67, 120-126
CrossRef70
Thomas A. B.Sanders. (2014) Protective effects of dietary PUFA against chronic disease: evidence from epidemiological studies and intervention trials. Proceedings of the Nutrition Society 73, 73-79
CrossRef71
Trevor A.Mori. (2014) Dietary n-3 PUFA and CVD: a review of the evidence. Proceedings of the Nutrition Society 73, 57-64
CrossRef72
Alicia H.Augustine, Lisa M.Lowenstein, William S.Harris, Gregory C.Shearer, Robert C.Block. (2014) Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 90, 69-75
CrossRef73
HassanFares, Carl J.Lavie, James J.DiNicolantonio, James H.O’Keefe, Richard V.Milani. (2014) Omega-3 Fatty Acids: A Growing Ocean of Choices. Current Atherosclerosis Reports 16
CrossRef74
Brian S.Katz, Kelly D.Flemming. (2014) Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. Neurosurgical Focus 36, E10
CrossRef75
Kieran F.Docherty, SandoshPadmanabhan. Genomics and Pharmacogenomics of Lipid-Lowering Therapies. 2014:, 715-746.
CrossRef76
LászlóBajnok. (2014) HDL vagy non-HDL: az itt a kérdés. A residualis dyslipidaemia gyógyszeres kezelésének lehetőségei. Orvosi Hetilap 155, 62-68
CrossRef77
B. S.Peskin. (2014) Why Fish Oil Fails: A Comprehensive 21st Century Lipids-Based Physiologic Analysis. Journal of Lipids 2014, 1-15
CrossRef78
IngridMühlhauser. (2014) Zur Überschätzung des Nutzens von Prävention. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 108, 208-218
CrossRef79
AlexanderTenenbaum, RobertKlempfner, Enrique ZFisman. (2014) Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovascular Diabetology 13, 159
CrossRef80
Trevor A.Mori. (2014) Omega-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors. Food & Function 5, 2004
CrossRef81
ToshiharuNinomiya, MasaharuNagata, JunHata, YoichiroHirakawa, MioOzawa, DaigoYoshida, TomoyukiOhara, HiroKishimoto, NaokoMukai, MasayoFukuhara, TakanariKitazono, YutakaKiyohara. (2013) Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: The Hisayama Study. Atherosclerosis 231, 261-267
CrossRef82
William S.Harris, Thomas D.Dayspring, Terrance J.Moran. (2013) Omega-3 Fatty Acids and Cardiovascular Disease: New Developments and Applications. Postgraduate Medicine 125, 100-113
CrossRef83
A.Sekikawa, C.Shin, K. H.Masaki, E. J. M.Barinas-Mitchell, N.Hirooka, B. J.Willcox, J.Choo, J.White, R. W.Evans, A.Fujiyoshi, T.Okamura, K.Miura, M. F.Muldoon, H.Ueshima, L. H.Kuller, K.Sutton-Tyrrell, . (2013) Association of Total Marine Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acids, With Aortic Stiffness in Koreans, Whites, and Japanese Americans. American Journal of Hypertension 26, 1321-1327
CrossRef84
T.Hoshi, R.Xu, S.Hou, S. H.Heinemann, Y.Tian. (2013) A point mutation in the human Slo1 channel that impairs its sensitivity to omega-3 docosahexaenoic acid. The Journal of General Physiology 142, 507-522
CrossRef85
VladRatziu. (2013) Pharmacological agents for NASH. Nature Reviews Gastroenterology & Hepatology 10, 676-685
CrossRef86
Sophie MarleneGrenon, Michael SConte. (2013) n-3 polyunsaturated fatty acids to heal the broken heart. Clinical Lipidology 8, 497-500
CrossRef87
Nanette C.Schloot. (2013) Omega-3-Fettsäuren wirken nicht wie erhofft gegen Arteriosklerosefolgen. Info Diabetologie 7, 31-31
CrossRef88
Gerald F.Watts, Esther M. M.Ooi, Dick C.Chan. (2013) Demystifying the management of hypertriglyceridaemia. Nature Reviews Cardiology 10, 648-661
CrossRef89
AndreaMessori, ValeriaFadda, DarioMaratea, SabrinaTrippoli. (2013) Omega-3 polyunsaturated fatty acids for patients at risk of sudden cardiac death and ventricular arrhythmias: Trial sequential analysis. Heart & Lung: The Journal of Acute and Critical Care 42, 391-392
CrossRef90
(2013) n–3 Fatty Acids in Patients with Cardiac Risk Factors. New England Journal of Medicine 369:8, 780-782
Free Full Text91
S.Stivala, M. F.Reiner, C.Lohmann, T. F.Luscher, C. M.Matter, J. H.Beer. (2013) Dietary -linolenic acid increases the platelet count in ApoE-/- mice by reducing clearance. Blood 122, 1026-1033
CrossRef92
ClaudioBilato. (2013) n-3 Fatty acids and cardiovascular disease: the story is not over yet. Aging Clinical and Experimental Research 25, 357-363
CrossRef93
MeganCully. (2013) Prevention: n-3 fatty acids provide little benefit. Nature Reviews Cardiology 10, 365-365
CrossRef94
RB. (2013) Prävention mit Fischöl gerät ins Schwimmen. MMW - Fortschritte der Medizin 155, 6-6
CrossRef95
Brian ScottPeskin. (2013) RETRACTED: Why Fish Oil Fails to Prevent or Improve CVD: A 21st Century Analysis. Food and Nutrition Sciences 04, 76-85
CrossRef
- Letters
